New triple-threat weapon needed in war between man and microbe

Mar 24, 2008
New triple-threat weapon needed in war between man and microbe
Without a breakthrough, microbial resistance might be inevitable in humanity's struggle against infectious disease, a medicinal chemist reports. Above is a color-enhanced scanning electron micrograph showing Salmonella typhimurium (red) invading cultured human cells. Courtesy of National Institute of Allergy and Infectious Diseases of the NIH

Mankind’s age-old battle against infectious diseases stands to rage on and on, unless scientists develop a new generation of triple-action antibiotics, according to an article scheduled for the March 28 issue of ACS’ monthly Journal of Natural Products.

In the article, Lester A. Mitscher presents a “rather personalized” account of the turbulent tug-of-war between microbes and mankind, describing past tactics, lessons learned, and a cautious prediction about the road ahead.

Mitscher notes, for instance, that “miracle drugs” in the 1940s and ’50s failed to live up to expectations. Though penicillin promised an end to infections worldwide in 1941, reports of resistant bacteria appeared only a year later. “Significant clinical resistance is now known for virtually all antibiotics in medical use,” the article states. “Unfortunately, the problem is getting worse since big pharma has largely withdrawn from research directed toward new antibiotic discovery.”

The review concludes that microbial resistance is inevitable pending unforeseen breakthroughs. One involves development of new antibiotics that go beyond killing or slowing the growth of disease-causing microbes. Those new medications would contain antimutagenic ingredients that discourage bacteria from mutating into resistant forms. In addition, they would pack immunostimulants that enlist the body’s own immune defense system to fight off an infection.

“Continued close observation and exploitation of natural phenomena appear at present to be the wisest course for scientists to follow in trying to deal with this problem,” says Mitscher.

Source: ACS

Explore further: Researchers develop novel method for making electrical cellulose fibers

add to favorites email to friend print save as pdf

Related Stories

'Zombie' bacteria are nothing to be afraid of

Aug 28, 2014

A cell is not a soap bubble that can simply pinch in two to reproduce. The ability to faithfully copy genetic material and distribute it equally to daughter cells is fundamental to all forms of life. Even ...

Foiling bugs that foil drugs

Aug 12, 2014

Every week, faculty members in the department of chemistry meet over lunch to discuss current literature in the field. The conversation at one of these meetings led Marcos Pires to what he calls a "crazy ...

Recommended for you

New material steals oxygen from the air

20 hours ago

Researchers from the University of Southern Denmark have synthesized crystalline materials that can bind and store oxygen in high concentrations. Just one spoon of the substance is enough to absorb all the ...

Driving cancer cells to suicide

20 hours ago

Ludwig Maximilian University of Munich researchers report that a new class of chemical compounds makes cancer cells more sensitive to chemotherapeutic drugs. They have also pinpointed the relevant target ...

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

zbarlici
not rated yet Mar 24, 2008
triple-action antibiotics? First we`d better see a quadruple-action antibiotic policy in place worldwide, aimed at ensuring proper use of antibiotics, as from what i understand there is too much abuse of antibiotic use as it is, in a sense that it is relied on too much and it is improperly used...
Soylent
not rated yet Mar 25, 2008
Currently drug companies develop drugs that can be patented and sold at a large markup to cover R&D costs and generate a profit.

Perhaps it would be better if society could put out a large bounty on drug treatments for all diseases in proportion to what curing or controling them is worth to society and only allow this bounty to be collected upon meeting specific demands for efficacy, safety and at the expense of not patenting the drug. That would allow society a good measure of control over which diseases are targeted by drug companies.